Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulgent Genetics, Inc.FLGT · Entity 2545 | President and COO | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulgent Genetics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 359,924 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 2,127 · Balance 359,924 F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. F2: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 220,816 |
Reported balance
Holding disclosure · report date 2026-09-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 220,816 F3: Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
F2: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2024 Filed Jun 4, 2024 20:57 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 404 | $20.65 | $8,342.60 |
DisclosureSEC source: 0000950170-24-068794 · ownership.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 354,543 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:57 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,075 | $20.65 | $22,198.75 |
DisclosureSEC source: 0000950170-24-068794 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 354,947 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:22 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 653 | $21.14 | $13,804.42 |
DisclosureSEC source: 0000950170-24-065241 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,022 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:22 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 6,719 | $21.50 | $144,458.50 |
DisclosureSEC source: 0000950170-24-054561 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,675 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 20:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,344 | $20.10 | $87,314.40 |
DisclosureSEC source: 0000950170-24-050516 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,394 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:28 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 404 | $23.24 | $9,388.96 |
DisclosureSEC source: 0000950170-24-026011 · ownership.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,738 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:28 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,075 | $23.24 | $24,983.00 |
DisclosureSEC source: 0000950170-24-026011 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,142 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 25,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-022463 · ownership.xml · nonDerivative · entry 5 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369,217 F5 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after February 26, 2024, and 1/12th of such shares vesting at the end of every three month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 3,418 | $24.26 | $82,920.68 |
DisclosureSEC source: 0000950170-24-022463 · ownership.xml · nonDerivative · entry 4 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,867 F4 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,111 | $24.26 | $51,212.86 |
DisclosureSEC source: 0000950170-24-022463 · ownership.xml · nonDerivative · entry 3 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,285 F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 6,359 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-022463 · ownership.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,396 F2 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 3,927 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-022463 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,037 F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 28, 2022. Read SEC document |
| February 26, 2024 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,551 | $16.24 | $73,908.24 |
DisclosureSEC source: 0000950170-25-029434 · ownership.xml · nonDerivative · entry 8 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,338 F8 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. Read SEC document |
| February 25, 2024 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 8,031 | $16.29 | $130,824.99 |
DisclosureSEC source: 0000950170-25-029434 · ownership.xml · nonDerivative · entry 6 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,585 F6 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 26, 2024. Read SEC document |
| February 25, 2024 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,951 | $16.29 | $48,071.79 |
DisclosureSEC source: 0000950170-25-029434 · ownership.xml · nonDerivative · entry 5 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,616 F5 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:52 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,612 | $24.06 | $62,844.72 |
DisclosureSEC source: 0000950170-24-021519 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,110 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| February 03, 2024 Filed Feb 7, 2024 00:26 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 6,719 | $24.65 | $165,623.35 |
DisclosureSEC source: 0000950170-24-011857 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,722 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:21 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,683 | $25.60 | $119,884.80 |
DisclosureSEC source: 0000950170-24-008853 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,441 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| December 11, 2023 Filed Dec 14, 2023 01:49 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 12,000 | $26.69 | $320,274.00 |
DisclosureSEC source: 0001209191-23-058570 · doc4.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,124 F2 · price: The shares were sold in multiple transactions at prices ranging from $26.61 to $26.92, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 11, 2023 Filed Dec 14, 2023 01:49 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 10,000 | $26.32 | $263,179.00 |
DisclosureSEC source: 0001209191-23-058570 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,124 F1 · price: The shares were sold in multiple transactions at prices ranging from $26.26 to $26.57, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 23:00 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,779 | $27.57 | $49,052.72 |
DisclosureSEC source: 0001209191-23-057670 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 385,124 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 3, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $27.25 to $27.79, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:30 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,617 | $27.25 | $44,065.03 |
DisclosureSEC source: 0001209191-23-056063 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 386,903 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $27.02 to $27.54, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 03, 2023 Filed Nov 7, 2023 22:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 7,669 | $26.94 | $206,602.86 |
DisclosureSEC source: 0001209191-23-054622 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 388,520 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 21:27 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 19,833 | $24.03 | $476,487.83 |
DisclosureSEC source: 0001209191-23-053874 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,189 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units held by the reporting person and assumed by the Issuer on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 20:37 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,492 | $31.41 | $46,860.59 |
DisclosureSEC source: 0001209191-23-048935 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,022 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $31.345 to $31.56, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 20:43 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,307 | $33.88 | $44,282.60 |
DisclosureSEC source: 0001209191-23-046720 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,514 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $33.55 to $34.19, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:38 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 6,198 | $40.08 | $248,415.84 |
DisclosureSEC source: 0001209191-23-044860 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 418,821 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 21:26 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 775 | $38.83 | $30,093.25 |
DisclosureSEC source: 0001209191-23-044509 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,019 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:11 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,433 | $40.30 | $57,744.31 |
DisclosureSEC source: 0001209191-23-034803 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,794 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $39.79 to $40.75, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:23 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,320 | $35.46 | $46,810.24 |
DisclosureSEC source: 0001209191-23-031001 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,227 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $34.96 to $36.15, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 03, 2023 Filed May 5, 2023 21:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 6,198 | $29.33 | $181,787.34 |
DisclosureSEC source: 0001209191-23-027775 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,547 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| May 01, 2023 Filed May 3, 2023 21:28 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 775 | $29.90 | $23,172.50 |
DisclosureSEC source: 0001209191-23-027090 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,745 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:36 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,045 | $31.85 | $128,833.25 |
DisclosureSEC source: 0001209191-23-015564 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,520 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:27 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 433 | $32.67 | $14,146.11 |
DisclosureSEC source: 0001209191-23-014113 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,565 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:23 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 741 | $31.65 | $23,452.65 |
DisclosureSEC source: 0001209191-23-013297 · doc4.xml · nonDerivative · entry 3 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,998 F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:23 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 14,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013297 · doc4.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,739 F2 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after February 23, 2023, and 1/12th of such shares vesting at the end of every three month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:23 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 2,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013297 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,166 F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 28, 2022. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:07 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,018 | $33.99 | $34,601.82 |
DisclosureSEC source: 0001209191-23-010753 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,024 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,408 | $36.21 | $159,613.68 |
DisclosureSEC source: 0001209191-23-007608 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,042 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:26 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 624 | $34.75 | $21,684.00 |
DisclosureSEC source: 0001209191-23-006860 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,450 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 22:07 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 685 | $34.39 | $23,559.34 |
DisclosureSEC source: 0001209191-22-059453 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,074 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $34.0900 to $35.2750, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:20 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,306 | $35.89 | $46,873.12 |
DisclosureSEC source: 0001209191-22-057844 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,759 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $35.515 to $36.370, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 07, 2022 Filed Nov 10, 2022 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 220,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-056317 · doc4.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 220,816 F3 · kind: At the effective time of the Merger, each issued and outstanding share of Fulgent Pharma preferred stock was converted into 0.02314 shares of Fulgent Genetics common stock, par value $0.0001 per share. Of the 220,816 shares of common stock issued to Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Dynasty Trust") in connection with the Merger, of which 104,098 shares are currently being held in escrow and following the expiration of the indemnification periods set forth in the Merger Agreement, shall be issued pro rata to the Trust in accordance with the terms of the Merger Agreement. F4 · ownership.nature: Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein. Read SEC document |
| November 07, 2022 Filed Nov 10, 2022 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 129,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-056317 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,065 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 (the "Merger Agreement") by and among Fulgent Genetics, Inc. ("Fulgent Genetics"), FG Merger Sub, Inc. ("FG"), Fulgent Pharma Holdings, Inc. ("Fulgent Pharma"), and the stockholders listed therein, FG merged with and into Fulgent Pharma (the "Merger"), with Fulgent Pharma being the surviving corporation following the Merger. At the effective time of the Merger (the "Effective Time"), each award of restricted stock units ("RSUs") based on Fulgent Pharma common stock that was outstanding immediately prior to the Effective Time ("Fulgent Pharma RSUs") was assumed and converted into the right to receive RSUs based on the common stock of Fulgent Genetics with the same terms and conditions as the Fulgent Pharma RSUs immediately prior to the Effective Time, subject to the applicable exchange ratio. F2 · kind: (continued from footnote 1) Twenty-five percent (25%) of the shares subject to RSUs reported herein will vest on the first anniversary of the date of the award, October 26, 2022, and 1/16th of the shares will vest every three months over the remaining 36-month period, subject to continued service for Issuer on each vesting date. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 22:08 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 6,198 | $37.89 | $234,842.22 |
DisclosureSEC source: 0001209191-22-055974 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,756 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:52 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 775 | $40.25 | $31,193.75 |
DisclosureSEC source: 0001209191-22-055527 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,954 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 21:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 675 | $44.18 | $29,823.53 |
DisclosureSEC source: 0001209191-22-048269 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,729 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $43.90 to $44.93, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 21:06 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,414 | $48.89 | $69,136.82 |
DisclosureSEC source: 0001209191-22-046869 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,404 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $48.67 to $49.02, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:12 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 6,343 | $62.93 | $399,164.99 |
DisclosureSEC source: 0001209191-22-044567 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,818 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:36 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 872 | $59.54 | $51,918.88 |
DisclosureSEC source: 0001209191-22-044281 · doc4.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,161 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.